Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Cori Daines
Professor, Pediatrics - (Clinical Scholar Track)
Pediatrics
Full Page
Overview
Research
More
Collaboration
(26)
Kenneth Knox
Mutual work: 1 Publication
Collaboration Details
Fernando Martinez
Mutual work: 3 Proposals﹒2 Publications﹒1 Grant
Collaboration Details
Wayne Morgan
Mutual work: 2 Grants﹒8 Publications﹒6 Proposals
Collaboration Details
Lynn Gerald
Mutual work: 2 Proposals﹒2 Publications
Collaboration Details
Christian Bime
Mutual work: 1 Publication
Collaboration Details
Page 1 of 6
Previous page
Next page
Grants
(90)
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeru
Active
·
2024
·
$306.4K
·
External
Principal Investigator (PI)
clinical trials,
cystic fibrosis,
nebulized drug delivery,
respiratory diseases,
pharmacology
Therapeutics Development Center Award
Active
·
2024
·
$1.5M / $150.5K
·
External
Principal Investigator (PI)
therapeutics,
development,
award
TDN Network Operations Support Position
Active
·
2024
·
$230.4K / $115.2K
·
External
Principal Investigator (PI)
network operations,
technical support,
telecommunications,
information technology,
troubleshooting
Cystic Fibrosis Learning Center Network Award
Active
·
2024
·
$840K / $84K
·
External
Principal Investigator (PI)
cystic fibrosis,
education,
healthcare,
network,
award
A Multicentre, Randomised, Double-blind, Parallel Group,Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eos
Active
·
2023
·
$0 / $2.9M
·
External
asthma,
pediatric patients,
clinical trial,
drug treatment
Page 1 of 18
Previous page
Next page
Publications
(67)
Recent
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study
2023
cystic fibrosis,
efficacy,
long-term safety,
elexacaftor,
tezacaftor
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor
2022
quality of life,
cystic fibrosis,
health,
elexacaftor,
tezacaftor
Bronchoalveolar lavage profiles in uncontrolled wheezy children compared by asthma predictive index
2022
pediatric asthma,
respiratory infections,
lung inflammation,
diagnostic markers,
pediatric pulmonology
Childhood Respiratory Conditions: Nonasthma Chronic Lung Disease
2022
respiratory conditions,
childhood health,
chronic lung disease,
nonasthma conditions,
pediatric pulmonology
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study
2021
cystic fibrosis,
efficacy,
safety
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
2021
clinical trials,
cystic fibrosis,
leukotriene inhibitors,
adult subjects
S66 Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis homozygous for F508del F/F) results from a Phase 3 clinical study
2021
cystic fibrosis,
triple combination therapy,
health-related quality of life,
f508del mutation
Diagnostic Accuracy of Nasopharyngeal Swab Cultures in Children Less Than Five Years with Chronic Wet Cough
2021
respiratory infections,
pediatrics,
diagnostic testing,
bacteriology,
chronic cough
The Future of Highly Effective Modulator Therapy in Cystic Fibrosis.
2021
cystic fibrosis,
therapy,
modulator,
future,
effective
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR EXTEND) an open-label extension study.
2021
cystic fibrosis,
long-term safety,
efficacy of tezacaftor-ivacaftor,
phe508del cftr
